Recently, Zhejiang Anglikang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") has received the Approval Notice for Supplementary Application of Chemical Active Pharmaceutical Ingredient issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant details are hereby announced as follows:
I. Basic Information of the Approval Document
Name of the Chemical Active Pharmaceutical Ingredient: Cefadroxil
Registration Number: Y20190007306
Manufacturer Name: Zhejiang Anglikang Pharmaceutical Co., Ltd.
Manufacturer Address: No. 1000 North Shengzhou Avenue, Shengzhou City, Shaoxing
Content of Application: Modification of API production process; Modification of registration standards
Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, the application items of this product meet the relevant requirements for drug registration. The following supplementary application items of this product are approved: 1. Modification of API production process (change from chemical synthesis process to enzymatic synthesis process); 2. Modification of quality standards.
II. Basic Information of the Product
The Company obtained the registration certificate (Approval No. H20093188) for the chemical API Cefadroxil (produced by chemical synthesis process) in February 2009. This product is the chemical API Cefadroxil prepared by the Company with a new process. After completing relevant research and upgrading quality standards, the Company submitted an application for modification to NMPA in June 2023, which was accepted.
This product is indicated for infectious diseases caused by Cefadroxil-sensitive bacteria such as staphylococci, streptococci and pneumococci, including respiratory tract infections, skin and soft tissue infections, oral infections, gastrointestinal tract infections, as well as otitis media and other conditions.












